ArticleClinical & experimental metastasis2026
Encapsulated histopathological growth pattern of colorectal liver metastases predicts prolonged survival after repeat liver resection for recurrence.
Article in Clinical & experimental metastasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The encapsulated histopathological growth pattern (HGP) of colorectal liver metastases (CRLMs) has been reported as a favorable prognostic factor. However, its prognostic relevance in patients undergoing treatment for recurrence after liver resection remains unclear. This study aimed to evaluate the impact of encapsulated HGP on time to surgical failure (TSF) following liver resection, and to assess whether encapsulated HGP at initial resection is associated with outcomes after repeat resection for recurrence. We retrospectively analyzed 272 patients who underwent initial liver resection for CRLMs. HGPs were classified and their associations with postoperative outcomes were examined. 61 patients were classified as having encapsulated HGP. Patients with encapsulated HGP had significantly longer TSF after liver resection than those with non-encapsulated HGP (p < 0.01). Multivariate analysis identified encapsulated HGP as an independent factor for improved TSF (Hazard ratio: 0.35, p < 0.01). Recurrence occurred less frequently in encapsulated HGP than in non-encapsulated HGP (63.9% vs 79.2%, p = 0.02). In addition, patients with encapsulated HGP had a lower incidence of multi-organ recurrence and a higher repeat resection rate for recurrence (64.1% vs 45.6%, p < 0.01). Among patients with repeat liver resection for recurrent CRLMs, post-recurrence survival was significantly longer in encapsulated HGP than in non-encapsulated HGP (p = 0.01) and encapsulated HGP at initial resection was identified as an independent factor of favorable survival after repeat liver resection (Hazard ratio: 0.09, p = 0.04). Encapsulated HGP was associated with improved TSF following liver resection for CRLMs. HGPs at initial resection may predict survival after repeat liver resection for recurrent CRLMs.
Indexed as
Identifiers
41848912What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.